Merck completes $3.4bn acquisition of SpringWorks Therapeutics, strengthening rare tumour treatment portfolio.

From Yahoo Finance: 2025-07-02 07:03:00

Merck KGaA has finalized the acquisition of SpringWorks Therapeutics for $3.4bn, adding two products targeting rare tumours to its portfolio. Ogsiveo and Gomekli have FDA approvals, with potential in the European market. The deal is expected to enhance Merck’s financial position and strengthen its focus on rare diseases.

Merck’s CEO Belén Garijo highlights the strategic importance of the SpringWorks acquisition, marking a significant step for the company’s healthcare business. The deal underscores Merck’s commitment to pursuing opportunities that align with its long-term goals and create value across its business sectors.

The integration of SpringWorks’ portfolio will strengthen Merck’s position in developing treatments for rare tumours. This includes gaining commercialisation rights for pimicotinib from Abbisko Therapeutics, emphasizing the company’s dedication to advancing innovative therapies for patients in need.

Following the acquisition, trading of SpringWorks shares on Nasdaq has ceased, with shareholders receiving $47 per share in cash from Merck. The deal marks a significant milestone for both companies and underscores Merck’s commitment to expanding its healthcare portfolio through strategic acquisitions.

Read more: Merck concludes SpringWorks acquisition for $3.4bn